WebDoctor Encyclopedia

Childhood Genitourinary

Congenital mesoblastic nephroma

Congenital mesoblastic nephroma is a rare kidney tumour of newborns and young babies, often seen on pregnancy scans. It has low malignant potential, and removing the affected kidney cures almost all infants, with about 97% alive at five years.

Medically reviewed Last reviewed October 19, 2026

What is congenital mesoblastic nephroma?

Congenital mesoblastic nephroma (CMN) is a rare kidney tumour of newborn babies and young infants. It is the most common kidney tumour in the first few months of life, and it is often found before birth on a pregnancy scan or in the first weeks after delivery.

CMN accounts for roughly 5% of all childhood kidney tumours (Vokuhl et al., 2018). It is considered a tumour of low malignant potential. In most babies, it does not spread, and removing the affected kidney cures it (Gooskens et al., 2017).

There are three types under the microscope: classic, cellular and mixed. The cellular type often carries a gene fusion called ETV6-NTRK3, the same change found in infantile fibrosarcoma, a soft tissue tumour of infants. This fusion can be targeted with modern drugs if the tumour comes back or cannot be removed.

Although the outlook is excellent, newborns are fragile, so the timing and type of treatment need careful planning by a specialist children’s cancer team.

1. Key facts at a glance

Feature Details
Type of tumour Kidney tumour of infancy with low malignant potential
How common About 5% of childhood kidney tumours
Typical age Before birth to 3 months; most are diagnosed under 6 months
Sex Slightly more common in boys
Subtypes Classic, cellular and mixed
Key gene change ETV6-NTRK3 fusion in many cellular tumours
Typical presentation Abdominal lump, sometimes found on pregnancy scans
Main treatment Surgical removal of the kidney (nephrectomy)
Outlook Excellent; about 97% survival at 5 years

2. The three subtypes

Subtype Share of cases Appearance Behaviour
Classic About half Bundles of bland spindle cells, like a fibrous scar Very low risk of recurrence
Cellular About a third Densely packed cells with more cell division Higher risk of recurrence, especially without the fusion
Mixed The rest Areas of both patterns Intermediate

Proportions come from a German and SIOP series of 111 children (Vokuhl et al., 2018).

3. Causes and risk factors

The cause of CMN is not known. It develops during pregnancy, while the baby’s kidney is still forming.

Point Details
Inheritance Not inherited; parents did nothing to cause it
Gene fusion ETV6-NTRK3 develops in the tumour cells of many cellular CMNs
Other gene changes Some classic tumours carry changes in the EGFR gene
Link with infantile fibrosarcoma The cellular type is thought to be the kidney counterpart of this tumour

There is no known lifestyle, diet or environmental cause, and nothing can be done during pregnancy to prevent it.

4. How does it look

Before birth

Feature Description
Pregnancy scan A solid mass in one of the baby’s kidneys
Polyhydramnios Excess amniotic fluid around the baby is common
Early delivery Premature birth occurs more often

On scans after birth

Feature Description
Ultrasound A solid kidney mass, sometimes with a ring of blood vessels around its edge
Size Often large compared with the baby’s size
Cystic areas More common in the cellular type
Spread Usually none at diagnosis

Under the microscope

Feature Classic Cellular
Cells Thin, bland spindle cells Plump, crowded cells
Pattern Interlacing bundles that extend into the kidney Sheets with pushing borders
Mitoses Few Many
Fusion test Negative Positive in more than half

5. Symptoms

Common signs in babies

  • A firm lump in the tummy, often noticed by parents or at the newborn check
  • A swollen abdomen
  • High blood pressure, which may only be found on testing
  • Blood in the urine (less common)
  • Vomiting or poor feeding, when the tumour presses on the gut
Problem What it means
High calcium (hypercalcaemia) May cause poor feeding, vomiting or constipation
High blood pressure The tumour can release renin, a hormone that raises blood pressure
Increased urine output Linked with high calcium or kidney effects

During pregnancy

Sign Notes
Excess amniotic fluid The mother’s tummy may grow faster than expected
Fetal distress or early labour Occasionally

When to seek medical advice

See a doctor if your baby has a lump or swelling in the tummy, blood in the nappy, repeated vomiting or poor feeding. Most tummy lumps in babies are caused by harmless conditions, but they always need a check.

Diagnosis before birth

When a kidney mass is seen on a pregnancy scan, the pregnancy is usually followed more closely in a fetal medicine unit. Doctors monitor the amount of amniotic fluid, the size of the mass and the baby’s wellbeing.

Parents meet the paediatric surgeons before delivery to plan care after birth. Most babies can be born vaginally, and delivery is planned at a hospital with neonatal intensive care and paediatric surgery on site.

6. Diagnosis

Test Purpose
Abdominal ultrasound First scan; shows the solid kidney mass
MRI or CT Shows the size, the blood vessels and the relationship to other organs
Chest imaging Checks for rare lung spread
Blood tests Kidney function, calcium, blood count
Blood pressure monitoring Detects high blood pressure
Pathology after surgery Confirms CMN and identifies the subtype
Molecular testing Looks for the ETV6-NTRK3 fusion

In most babies, the diagnosis is confirmed after the kidney is removed, rather than by needle biopsy. The main condition to tell apart is Wilms tumour, which is much more common in older infants and toddlers.

Kidney tumours in babies compared

Tumour Usual age Typical treatment Outlook
Congenital mesoblastic nephroma Before birth to 6 months Surgery alone in most cases Excellent
Wilms tumour Mostly 1-5 years; rare in newborns Surgery and chemotherapy, sometimes radiotherapy Very good
Rhabdoid tumour of the kidney Usually under 2 years Intensive multimodal treatment Poor
Clear cell sarcoma of the kidney Usually 1-4 years Surgery, chemotherapy and radiotherapy Good

Staging

Childhood kidney tumours are usually staged after surgery:

Stage Description
Stage I Tumour confined to the kidney and completely removed
Stage II Tumour extends beyond the kidney but is completely removed
Stage III Tumour left behind after surgery, tumour spill or lymph node involvement
Stage IV Spread to distant organs (rare)

7. Treatment

Treatment is carried out by a paediatric surgical and oncology team, often with neonatal intensive care specialists.

Surgery

Aspect Details
Operation Removal of the affected kidney and tumour (radical nephrectomy)
Approach Usually open surgery; keyhole surgery in selected cases
Goal Complete removal without rupturing the tumour
Timing Planned carefully in newborns, balancing tumour size with the baby’s stability

Surgery alone cures most babies (Gooskens et al., 2017). A single-centre series of nine infants also concluded that surgery remains the mainstay, with chemotherapy and radiotherapy kept for tumours that cannot be removed or that come back (Pachl et al., 2020).

What to expect around surgery

Stage What happens
Before Scans, blood tests and stabilisation of blood pressure and calcium
Anaesthetic Given by a specialist paediatric anaesthetist
Operation Usually takes a few hours
After Care on a neonatal or paediatric intensive care unit or surgical ward
Feeding Usually restarted within a few days
Going home Often within a week or two, depending on the baby’s age and recovery
Results The pathology report, including subtype and fusion status, follows within 1-2 weeks

Treatment after surgery

Situation Usual approach
Classic or mixed CMN, completely removed Follow-up only
Cellular CMN, completely removed Usually follow-up only
Tumour left behind or ruptured Close monitoring; chemotherapy may be considered
Recurrence or spread Further surgery, chemotherapy, and sometimes radiotherapy

Targeted treatment

For tumours with an NTRK fusion that cannot be removed or that recur, TRK inhibitors such as larotrectinib can shrink the tumour. These drugs are taken by mouth and are generally well tolerated. Kinase fusions in infantile tumours such as CMN are often sensitive to these targeted drugs (Davis et al., 2022).

Supportive care

Problem Management
High blood pressure Medicines until the tumour is removed
High calcium Fluids and medicines
Prematurity Neonatal intensive care support
Feeding Nutritional support before and after surgery

8. Outlook (prognosis)

Measure Figure
5-year overall survival About 97%
5-year relapse-free survival About 93%
Classic type relapse-free survival About 98%
Cellular type relapse-free survival About 89%
Mixed type relapse-free survival About 80%

These figures come from 111 children treated in European studies (Vokuhl et al., 2018). All relapses in that series occurred in tumours without the ETV6-NTRK3 fusion. Among cellular tumours, those with the fusion did not relapse at all.

The main risks are recurrence within the first year, usually in cellular tumours, and complications of treatment in very young babies. The risk of treatment-related death is highest in the first weeks of life, which is why care in an experienced centre is important (Gooskens et al., 2017).

9. Follow-up

Follow-up Typical schedule
Abdominal ultrasound Every few months in the first 1-2 years, when recurrences usually happen
Chest imaging For higher-risk cases
Blood pressure and kidney function Regularly, as the child grows with one kidney
Growth and development Routine checks

Long-term health

Most children treated for CMN grow up healthy. Because they have one kidney, doctors usually recommend lifelong attention to blood pressure, urine protein and kidney function. Children who needed chemotherapy or radiotherapy have additional long-term follow-up for late effects of those treatments.

10. Living with congenital mesoblastic nephroma

  • One kidney is enough: children with a single healthy kidney usually grow and develop normally
  • Check blood pressure at routine visits throughout childhood
  • Tell other doctors that your child has one kidney
  • Avoid unnecessary anti-inflammatory medicines unless advised by a doctor
  • Encourage normal activity; discuss contact sports with your team when your child is older
  • Keep vaccinations up to date unless your child’s team advises otherwise
  • Keep copies of the surgery and pathology reports for future doctors
  • Treat urine infections promptly, as they matter more when there is only one kidney
  • Seek support from children’s cancer charities and family support services

Support for parents

Need Where to find help
Information Your child’s specialist nurse and oncology team
Emotional support Hospital psychologists, social workers and parent groups
Practical help Charities offering travel, accommodation and financial advice

11. Frequently asked questions

Question Answer
Is CMN cancer? It is a tumour with low malignant potential; most behave in a benign way after removal
Did something in pregnancy cause it? No known cause in pregnancy has been identified
Will my next baby be affected? It is not inherited, so the risk is not raised
Will my child need chemotherapy? Usually not; it is kept for tumours that recur or cannot be removed
Can my child live normally with one kidney? Yes, in almost all cases
Can CMN come back after surgery? Occasionally, mostly within the first year and usually in cellular tumours
Can my baby be breastfed? Yes; breastfeeding can usually continue before and after surgery
How is it different from Wilms tumour? CMN occurs earlier in life and usually needs surgery alone

12. Questions to ask your care team

  • What subtype is the tumour?
  • Was the tumour completely removed?
  • Does the tumour carry the ETV6-NTRK3 fusion?
  • What is the risk of recurrence for my baby?
  • How often will scans be needed?
  • Does my baby need blood pressure medicines before or after surgery?
  • Where should my baby be delivered if the tumour was found before birth?
  • Who should I call if my baby becomes unwell?

Resources

  1. Davis, J.L. et al. (2022) ‘Mesenchymal neoplasms with NTRK and other kinase gene alterations’, Histopathology, 80(1), pp. 4-18.
  2. Gooskens, S.L. et al. (2017) ‘Congenital mesoblastic nephroma 50 years after its recognition: a narrative review’, Pediatric Blood & Cancer, 64(7), e26437.
  3. Pachl, M. et al. (2020) ‘Congenital mesoblastic nephroma: a single-centre series’, Annals of the Royal College of Surgeons of England, 102(1), pp. 67-70.
  4. Vokuhl, C. et al. (2018) ‘ETV6-NTRK3 in congenital mesoblastic nephroma: a report of the SIOP/GPOH nephroblastoma study’, Pediatric Blood & Cancer, 65(4), e26925.
  5. National Cancer Institute (2026) Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/kidney/hp/wilms-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.